DE69931963D1 - Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden - Google Patents

Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden

Info

Publication number
DE69931963D1
DE69931963D1 DE69931963T DE69931963T DE69931963D1 DE 69931963 D1 DE69931963 D1 DE 69931963D1 DE 69931963 T DE69931963 T DE 69931963T DE 69931963 T DE69931963 T DE 69931963T DE 69931963 D1 DE69931963 D1 DE 69931963D1
Authority
DE
Germany
Prior art keywords
treatment
ischemic reperfusion
reperfusion damage
spla2 inhibitors
spla2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69931963T
Other languages
English (en)
Inventor
Satoru Todo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Application granted granted Critical
Publication of DE69931963D1 publication Critical patent/DE69931963D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heat Treatment Of Articles (AREA)
DE69931963T 1998-10-14 1999-10-07 Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden Expired - Lifetime DE69931963D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29242398 1998-10-14
PCT/JP1999/005528 WO2000021563A1 (fr) 1998-10-14 1999-10-07 Moyens de traitement et de prevention contre les troubles ischemiques dus a la repercussion

Publications (1)

Publication Number Publication Date
DE69931963D1 true DE69931963D1 (de) 2006-07-27

Family

ID=17781604

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69931963T Expired - Lifetime DE69931963D1 (de) 1998-10-14 1999-10-07 Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden

Country Status (7)

Country Link
US (1) US7098237B1 (de)
EP (1) EP1157704B1 (de)
AT (1) ATE329619T1 (de)
AU (1) AU6004799A (de)
CA (1) CA2346334A1 (de)
DE (1) DE69931963D1 (de)
WO (1) WO2000021563A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4623483B2 (ja) * 1999-08-23 2011-02-02 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有するピロロトリアジン誘導体
WO2002000621A1 (fr) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Composes inhibiteurs de la spla2 de type x
TWI314457B (de) * 2001-03-19 2009-09-11 Shionogi & Co
CA2460347A1 (en) 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 3-glyoxlylamideindoles for treating cancer
NZ531700A (en) 2001-09-13 2006-10-27 Synta Pharmaceuticals Corp 1-Glyoxylamide indolizines for treating cancer
US20060030620A1 (en) * 2004-08-04 2006-02-09 Chia-Yu Chang Method for treating and/or preventing ischemia/reperfusion injury
AU2006311761A1 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Indole compounds having C4-amide substituents and use thereof as phospholipase-A2 inhibitors
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
CA2747557A1 (en) * 2008-12-19 2010-06-24 Anthera Pharmaceuticals, Inc. Treatment of major adverse cardiac events and acute coronary syndrome using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies
BRPI1014405A2 (pt) 2009-04-29 2016-04-05 Amarin Corp Plc composições farmacêuticas compreendendo epa e um agente cardiovascular e métodos de seu uso
WO2012027579A1 (en) * 2010-08-26 2012-03-01 Concert Pharmaceuticals, Inc. Synthetic triterpenoid derivatives
AU2018260927B1 (en) * 2018-05-25 2019-02-21 Graham Sherard Baldwin Methods and compositions for inhibiting a noxious insult

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
JPH07285866A (ja) * 1994-02-22 1995-10-31 Eisai Co Ltd 臓器障害予防・治療・改善剤
MX9501608A (es) * 1994-04-01 1997-02-28 Lilly Co Eli 1h-indol-3-glioxilamidas inhibidoras de spla2.
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
CN1158121A (zh) 1994-07-21 1997-08-27 伊莱利利公司 吲哚嗪sPLA2抑制剂
US6214876B1 (en) 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
US5648331A (en) * 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
HUP9902120A3 (en) * 1995-12-13 1999-12-28 Lilly Co Eli Naphthyl glyoxamides as spla2 inhibitors
US6160175A (en) * 1995-12-13 2000-12-12 Eli Lilly And Company Naphthyl acetamides as sPLA2 inhibitors
JP2001503055A (ja) * 1996-10-30 2001-03-06 イーライ・リリー・アンド・カンパニー 置換三環化合物群
US5916922A (en) 1996-12-03 1999-06-29 Eli Lilly And Company Phenyl glyoxamides as SPLA2 inhibitors
US6353128B1 (en) 1996-12-03 2002-03-05 Eli Lilly And Company Phenyl acetamides as sPLA2 inhibitors
US5747590A (en) * 1996-12-04 1998-05-05 E. I. Du Pont De Nemours And Company Acrylic-melamine-functionalized oligomer coating composition
ID18983A (id) * 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
US5919774A (en) * 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
WO1998047507A1 (en) * 1997-04-24 1998-10-29 Shionogi & Co., Ltd. Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds
TW455581B (en) * 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides
WO1999009978A1 (en) * 1997-08-28 1999-03-04 Eli Lilly And Company Method for treatment of non-rheumatoid athritis
JP4412521B2 (ja) 1998-03-31 2010-02-10 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有するピロロ［１，２−ａ］ピラジン誘導体
CN1302300A (zh) * 1998-05-21 2001-07-04 盐野义制药株式会社 吡咯并[1,2－b]哒嗪sPLA2抑制剂

Also Published As

Publication number Publication date
EP1157704A4 (de) 2004-02-25
EP1157704A1 (de) 2001-11-28
WO2000021563A1 (fr) 2000-04-20
ATE329619T1 (de) 2006-07-15
US7098237B1 (en) 2006-08-29
CA2346334A1 (en) 2000-04-20
AU6004799A (en) 2000-05-01
EP1157704B1 (de) 2006-06-14

Similar Documents

Publication Publication Date Title
DE69910368D1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
DE69931963D1 (de) Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden
DE60011570D1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
NO20005237L (no) Heterocyklisk substituerte amider anvendt som calpain- inhibitorer
TR200002480T2 (tr) İzaşemi tedavisi için guanidin türevleri
SE9901272D0 (sv) New improved formulation
DE69912972D1 (de) Antibiotische zusammensetzungen zur behandlung des auges
DK1196414T3 (da) Prolægemiddel af carbamathæmmer for IMPDH
DK1273299T3 (da) Minoxidilinindeholdende praparater
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
DE60013266D1 (de) Steroidnitrate zur behandlung von oxidativen schädigungen und endothelialer dysfunktion
DE60026279D1 (de) Zusammenstellungen zur prophylaxe und behandlung von allergien des typus i
DE60009665D1 (de) Zusammensetzungen zur behandlung von entzündungsreaktionen
ATE312079T1 (de) Nichtnukleoside reverse transkriptase-hemmer zur behandlung von hiv-infektion
FI935777A0 (fi) Inhibitorer foer HIV-proteas anvaendbara vid behandling av AIDS
DE60029242D1 (de) Arzneien zur begleitenden behandlung von glaukomen
ATE232191T1 (de) Verfahren und zusammensetzung zur inhibierung der polymerisierung von ethylenisch ungesättigten kohlenwasserstoffen
ATE428425T1 (de) Spla2-inhibitoren zur behandlung von arteriosklerose
ES2096874T3 (es) Inhibidor de la proteasa de hiv util para el tratamiento del sida.
DE60133385D1 (de) (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen
NO20004920D0 (no) Anvendelse av proteaseinhibitorer for behandling av hudskader
ATE289510T1 (de) Sulfonylpyridazinone derivate zur behandlung von ischämischem gewebeschaden
WO2003041640A3 (en) METHODS FOR TREATING ISCHEMIC REPERFUSION INJURY USING IkB KINASE-BETA INHIBITORS
DE60000658D1 (de) Zusammensetzung zur behandlung von psoriasis
ATE390920T1 (de) Lipase inhibitoren zur behandlung von dyspepsia

Legal Events

Date Code Title Description
8332 No legal effect for de